CompletedPhase 2NCT01260454

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Rochester
Principal Investigator
R James White, MD, PhD
University of Rochester
Intervention
Qutenza (8% capsaicin)(drug)
Enrollment
6 enrolled
Eligibility
15-80 years · All sexes
Timeline
20102012

Study locations (1)

Collaborators

United Therapeutics

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01260454 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials